InVitria, a division of Ventria Bioscience, was founded with the goal of providing the biotechnology industry with innovative products to improve cell culture and biomanufacturing. InVitria does this by allowing customers to eliminate animal components from their cell-based processes. Removing these components helps improve consistency, safety and efficiency. InVitria’s products are recombinant proteins that are manufactured in our manufacturing facility in Junction City, Kansas.
Key Biologics provides biological products to the cell therapy industry worldwide. Non-mobilized and G-CSF mobilized MNC collections are performed under proprietary IRB-approved protocols. Three G-CSF schedules are available: 4day/10ug per kg/single collection, 5day/10ug per kg/single collection and 5day/5ug per kg/two collections. Key operates the Spectra, Optia and Amicus devices allowing customers to compare MNC product characteristics that could influence manufacturing of autologous or allogeneic cell-based therapies.
Kite Pharma is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do, from early research to product development. For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, transforming cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.
MaxCyte’s flow electroporation is driving the next generation of cell-based medicines. Used in the discovery, development, and manufacture of cell-based therapeutics, the MaxCyte GT® Flow Transfection System, MaxCyte STX® Scalable Transfection System, and MaxCyte VLX® Large Scale Transfection System enable the development of transfected cells for a range of applications.
Through cutting edge science, engineering and software, MedCision develops and commercializes standardization and automation technologies for vital preclinical and clinical sample handling. MedCision’s instrumentation will advance near patient drug management by providing controlled and scalable processing of temperature-sensitive products.
For over 36 years, Quick has been safely transporting human organs, tissue, blood and blood products, personalized medicine, and medical devices for the healthcare community, helping to save lives. QuickSTAT manages clinical trial logistics, transporting investigational drugs, clinical research specimens and biologics throughout the world, helping to bring new drugs to market… Read More
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customer.
A critical factor facing the Cell Therapy industry is choosing technologies and partners that can deliver scale. There’s no other field of medicine that requires the level of mass customization of production and careful orchestration of production pathways that cell therapies demand. From sample collection through logistics, manufacturing and final transplantation, TrakCel’s proven technology integrates and orchestrates every aspect of your Autologous and Allogeneic supply chains in a scalable, compliant and validated technology platform.
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, KTB etc, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide. www.carsgen.com